Elsevier

Clinical Therapeutics

Volume 28, Issue 11, November 2006, Pages 1764-1778
Clinical Therapeutics

Role of abatacept in the management of rheumatoid arthritis

https://doi.org/10.1016/j.clinthera.2006.11.020Get rights and content

Abstract

Background:

Rheumatoid arthritis (RA) has been associated with significant morbidity and economic burden. Traditional pharmacotherapy (eg, NSAIDs, corticosteroids, disease-modifying antirheumatic drugs [DMARDs]) can be inadequate in controlling symptoms and disease progression. Abatacept is the first selective co-stimulation modulator approved by the US Food and Drug Administration for the management of RA. It is a fusion protein developed to modulate the T -cell co-stimulatory signal that is mediated through the CD28-CD80/86 pathway.

Objective:

The objective of this manuscript was to review the clinical pharmacology, pharmacokinetic and pharmacodynamic properties, tolerability, and clinical efficacy of abatacept.

Methods:

MEDLINE and International Pharmaceutical Abstracts were searched through June and May, respectively, of 2006 using the term abatacept or CTLA4-Ig. All prospective, randomized, Phase II and III trials, and their extension phases, were included.

Results:

Phase II and III clinical trials found that abatacept, at a dose of 10 mg/kg administered as a short IV infusion in combination with DMARDs, was associated with significant clinical benefit in patients with active RA. After 6 months of treatment, the American College of Rheumatology (ACR) criteria for 20% clinical improvement (ACR20 response) was attained in 41.9% to 67.9% of patients who received abatacept compared with 19.5% to 39.7% of patients who received placebo (P < 0.001). The percentages of patients achieving the ACR criteria for 50% and 70% clinical improvement (ACR50 and ACR70) were 20.3% to 39.9% and 10.2% to 19.8%, respectively, in the groups that received abatacept compared with 3.8% to 16.8% and 1.5% to 6.5%, respectively, in the patients who received placebo (P = 0.03 and P < 0.001). Additionally, abatacept was found to improve disease activity, physical function, pain, and health-related quality of life (HRQOL). The most commonly reported adverse effects associated with abatacept treatment were headache (18.2%), upper respiratory tract infection (12.7%), nasopharyngitis (11.5%), and nausea (11.5%). The incidences of infections and serious infections were higher in the group that received abatacept compared with patients who received placebo (53.8% vs 48.3% and 3.0% vs 1.9%, respectively; P not reported). No significant between-group differences in mortality were found.

Conclusions:

Available evidence suggests that abatacept was effective in controlling symptoms and improving HRQOL in patients with active RA and an inadequate response to DMARD therapy. The most commonly reported adverse effects associated with abatacept treatment were headache, upper respiratory infection, nausea, and nasopharyngitis. Additional trials are needed to determine the long-term safety profile of this agent and whether the clinical benefits of abatacept found in the current clinical trials will be sustained over time.

References (35)

  • GreeneJ.L. et al.

    Covalent dimerization of CD28/ CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions

    J Biol Chem

    (1996)
  • LinsleyP.S. et al.

    Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors

    Immunity

    (1994)
  • American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines

    Guidelines for the management of rheumatoid arthritis: 2002 Update

    Arthritis Rheum

    (2002)
  • Arthritis prevalence rising as baby boomers grow older

    (2006)
  • CooperN.J.

    Economic burden of rheumatoid arthritis: A systematic review

    Rheumatology (Oxford)

    (2000)
  • YelinE. et al.

    An assessment of the annual and longterm direct costs: The impact of poor function and functional decline

    Arthritis Rheum

    (1999)
  • DoanT. et al.

    Rheumatoid arthritis: An overview of new and emerging therapies

    J Clin Pharmacol

    (2005)
  • Medical Subject Headings

    (2006)
  • MorelandL.W. et al.

    Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebocontrolled clinical trial evaluating CTLA4-Ig and LEA29Y eighty-five days after the first infusion

    Arthritis Rheum

    (2002)
  • KremerJ.M. et al.

    Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

    N Engl J Med

    (2003)
  • KremerJ.M. et al.

    Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

    Arthritis Rheum

    (2005)
  • Study IM101101

    (2006)
  • GenoveseM.C. et al.

    Abatacept for rheumatoid arthritis refractory to tumor necro sis factor alpha inhibition

    N Engl J Med

    (2005)
  • KremerJ.M. et al.

    Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial

    Ann Intern Med

    (2006)
  • CombeB. et al.

    Safety and patient-reported outcomes associated with abatacept in the treatment of rheumatoid arthritis patients who received background disease modifying anti-rheumatic drugs (DMARDS): The ASSURE trial. RA treatment: Biologics and gene therapy I

  • PeachR.J. et al.

    Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1

    J Exp Med

    (1994)
  • AbramsJ.R. et al.

    CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

    J Clin Invest

    (1999)
  • Cited by (34)

    • Use of In silico tools for screening buffers to overcome physical instability of Abatacept

      2022, Transplant Immunology
      Citation Excerpt :

      Also, eight tryptophan residues were located exclusively in the Fc domain and 30 tyrosine residues were distributed over both domains [12]. Abatacept, known as CTLA-4Ig; approved by the US Food and Drug Administration in December 2005 for the treatment of Rheumatoid arthritis [4,34]. The worldwide prevalence of Rheumatoid arthritis is between 0.18 and 1.07%, with an annual incidence of 0.01–0.05% [8,35].

    • Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412

      2011, Blood
      Citation Excerpt :

      CD28 is a potential target for both inhibition and stimulation of T-cell responses. Ligand blockade with recombinant CTLA4-Ig has entered the clinic,6 and blockade of CD28 itself by mAb or mAb fragments has been successful in rodent and primate models.7-9 With regard to T-cell stimulation, mAb have been developed that activate T cells without the need to ligate the TCR, making them polyclonal T-cell activators.10-12

    • Immunotoxicology of Biological Response Modifiers

      2010, Comprehensive Toxicology, Second Edition
    • Targeting lymphocyte activation to treat rheumatoid arthritis

      2009, Revue du Rhumatisme (Edition Francaise)
    • Targeting lymphocyte activation to treat rheumatoid arthritis

      2009, Joint Bone Spine
      Citation Excerpt :

      The proportion of patients with adverse events requiring study withdrawal was 5.5% with abatacept and 3.9% with the placebo, the serious adverse event rate was 13.6% vs. 12.3%, and mortality was 0.5% vs. 0.6%. A 2006 systematic literature review showed a small increase in the risk of infections and severe infections with abatacept compared to a placebo (infections, 54% vs. 48%; severe infections, 3% vs. 1%) [37]. A metaanalysis of the data from the phase II trials, ASSURE, AIM, and ATTAIN was therefore conducted to assess the risk of infection associated with abatacept therapy.

    View all citing articles on Scopus
    View full text